These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2110906)

  • 1. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.
    Jain D; Dasgupta P; Hughes LO; Lahiri A; Raftery EB
    Eur J Clin Pharmacol; 1990; 38(2):111-4. PubMed ID: 2110906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF; Pouleur H; Cocco G; Wolff AA
    Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
    Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
    Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
    J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antianginal efficacy and improved exercise performance with timolol. Twice-daily beta blockade in ischemic heart disease.
    Harris FJ; Low RI; Paumer L; Amsterdam EA; Mason DT
    Am J Cardiol; 1983 Jan; 51(1):13-8. PubMed ID: 6129794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
    J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
    Savarese G; Rosano G; D'Amore C; Musella F; Della Ratta GL; Pellegrino AM; Formisano T; Vitagliano A; Cirillo A; Cice G; Fimiani L; del Guercio L; Trimarco B; Perrone-Filardi P
    Int J Cardiol; 2013 Nov; 169(4):262-70. PubMed ID: 24063912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.
    Pepine CJ; Wolff AA
    Am J Cardiol; 1999 Jul; 84(1):46-50. PubMed ID: 10404850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.
    Bagger JP; Bøtker HE; Thomassen A; Nielsen TT
    Cardiovasc Drugs Ther; 1997 Jul; 11(3):479-84. PubMed ID: 9310277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ranolazine--an additional anti-anginal drug].
    Michels G; Kochanek M; Hoppe UC
    Dtsch Med Wochenschr; 2010 Oct; 135(41):2037-40. PubMed ID: 20925013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
    Timmis AD; Chaitman BR; Crager M
    Eur Heart J; 2006 Jan; 27(1):42-8. PubMed ID: 16176940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodynamic, anti-anginal and anti-ischaemic effects of sublingual nitroglycerin: dose-response, duration and time of onset of action.
    Nyberg G; Holmberg B
    Eur J Clin Pharmacol; 1988; 34(6):561-7. PubMed ID: 3139428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranolazine: a review of its use in chronic stable angina pectoris.
    Keating GM
    Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
    Koren MJ; Crager MR; Sweeney M
    J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
    Wenger NK; Chaitman B; Vetrovec GW
    Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.